<DOC>
	<DOCNO>NCT01369602</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetics , safety tolerability single oral dose PF-04991532 subject renal impairment .</brief_summary>
	<brief_title>Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Stable renal function define &lt; 20 % difference two measurement serum creatinine obtain two occasion separate least 72 hour 14 day ; second determination must obtain within 28day period prior start study medication administration . CrCl value Screening ( average two value obtain within two week apart dose ) use study enrollment . Body Mass Index ( BMI ) 17.5 40 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception outline protocol least 14 day prior first dose study medication . Subjects recent ( within last 6 month ) history myocardial infarction , unstable angina , coronary revascularization , stroke transient ischemic attack ( TIA ) . Subjects severe heart failure ( New York Heart Association Functional Class IV ) Screening . Subjects acute renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>